Sarcomatrix Opens New Funding Round to Advance Muscular Dystrophy Treatment

Las Vegas, Wednesday, 15 July 2026.
Sarcomatrix Therapeutics has launched a Seed+ funding round on KoreInside, aiming to transition its promising oral muscular dystrophy treatment into human clinical trials by 2027.